FIC20250034I1 - O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola - Google Patents

O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola

Info

Publication number
FIC20250034I1
FIC20250034I1 FIC20250034C FIC20250034C FIC20250034I1 FI C20250034 I1 FIC20250034 I1 FI C20250034I1 FI C20250034 C FIC20250034 C FI C20250034C FI C20250034 C FIC20250034 C FI C20250034C FI C20250034 I1 FIC20250034 I1 FI C20250034I1
Authority
FI
Finland
Prior art keywords
atropine
deuterated
deuterohemisulphate
salt
deuterohemisulphate salt
Prior art date
Application number
FIC20250034C
Other languages
English (en)
Finnish (fi)
Original Assignee
Sydnexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868660&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FIC20250034(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sydnexis Inc filed Critical Sydnexis Inc
Publication of FIC20250034I1 publication Critical patent/FIC20250034I1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIC20250034C 2014-06-24 2025-11-28 O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola FIC20250034I1 (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462016502P 2014-06-24 2014-06-24
US201462096433P 2014-12-23 2014-12-23
US201562151926P 2015-04-23 2015-04-23
US14/726,139 US9421199B2 (en) 2014-06-24 2015-05-29 Ophthalmic composition
PCT/US2015/037249 WO2015200361A1 (en) 2014-06-24 2015-06-23 Ophthalmic composition

Publications (1)

Publication Number Publication Date
FIC20250034I1 true FIC20250034I1 (fi) 2025-11-28

Family

ID=54868660

Family Applications (1)

Application Number Title Priority Date Filing Date
FIC20250034C FIC20250034I1 (fi) 2014-06-24 2025-11-28 O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola

Country Status (25)

Country Link
US (12) US9421199B2 (https=)
EP (3) EP3160471B1 (https=)
JP (6) JP6678362B2 (https=)
KR (4) KR102506109B1 (https=)
CN (3) CN106572998B (https=)
BR (1) BR112016030368B1 (https=)
CA (1) CA2953363C (https=)
CY (1) CY1125505T1 (https=)
DK (1) DK3160471T3 (https=)
ES (1) ES2924243T3 (https=)
FI (1) FIC20250034I1 (https=)
FR (1) FR25C1045I1 (https=)
HR (1) HRP20220972T1 (https=)
HU (2) HUE059521T2 (https=)
IL (1) IL249643B (https=)
LT (1) LT3160471T (https=)
NO (1) NO2025049I1 (https=)
PL (1) PL3160471T3 (https=)
PT (1) PT3160471T (https=)
RS (1) RS63486B1 (https=)
SG (3) SG11201610682UA (https=)
SI (1) SI3160471T1 (https=)
SM (1) SMT202200447T1 (https=)
TW (4) TW202510877A (https=)
WO (1) WO2015200361A1 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1211867A1 (en) 2012-08-24 2016-06-03 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
EP3302426A4 (en) * 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2017083167A1 (en) 2015-11-10 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
RU2747455C2 (ru) 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
WO2017177262A1 (en) * 2016-04-11 2017-10-19 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
CN117205209A (zh) * 2016-05-25 2023-12-12 新加坡保健服务集团 含有阿托品的水性组合物
PH12019501945B1 (en) * 2017-02-21 2024-02-21 Singapore Health Serv Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
SG11201907315PA (en) * 2017-03-23 2019-09-27 Singapore Health Serv Pte Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
FI3600456T3 (fi) 2017-03-27 2023-10-26 Regeneron Pharma Sterilointimenetelmä
US10251875B2 (en) * 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア，インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
CA3070556A1 (en) * 2017-07-20 2019-01-24 Alan Laboratories, Inc. Compositions and methods for treatment of myopia
US20200345542A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
AU2019205774B2 (en) 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression
CN110934869B (zh) * 2018-09-25 2023-07-04 沈阳兴齐眼药股份有限公司 一种阿托品药物组合物和药盒产品
CN114533652B (zh) * 2018-09-25 2024-12-13 沈阳兴齐眼药股份有限公司 药物组合物、其制备方法和用途
TW202045190A (zh) * 2019-02-06 2020-12-16 美商蒂克利爾公司 自包含錯合劑之眼用調配物移除保存劑之系統及方法
PT3701938T (pt) 2019-03-01 2024-01-31 Medivis S R L Formulações oftálmicas à base de atropina
AU2020248407C1 (en) * 2019-03-26 2025-12-04 Aura Biosciences, Inc. Human papillomavirus nanoparticle formulations
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CN114364355A (zh) * 2019-07-11 2022-04-15 犹他大学研究基金会 多剂眼科制剂和治疗方法
AU2020419590A1 (en) * 2019-11-15 2022-06-30 Silk Technologies, Ltd. Stable formulations of silk-derived protein
US12161585B2 (en) 2019-12-11 2024-12-10 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
IL293859A (en) * 2019-12-16 2022-08-01 Sydnexis Inc Ophthalmic preparations that include d2o
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
WO2022026796A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for delivering meibum-like materials
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN116785286B (zh) * 2020-10-10 2026-02-17 远大医学营养科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
KR102245533B1 (ko) * 2020-11-02 2021-04-28 주식회사 지게차코리아 운송수단용 림 및 이의 제조방법
US11872213B2 (en) * 2021-01-28 2024-01-16 Glaukos Corporation Formulations
MX2023009091A (es) 2021-02-03 2023-08-09 Ads Therapeutics Llc Composiciones oftalmologicas topicas.
US20240139166A1 (en) * 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia
WO2022172089A1 (en) * 2021-02-12 2022-08-18 I Optima Ltd. Compound, method and system for ophthalmic surgery
PE20241644A1 (es) * 2021-03-16 2024-08-09 Vyluma Inc Envase multi-dosis para composiciones oftalmica
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
KR20240052048A (ko) * 2021-09-13 2024-04-22 오우푸시팡 파마수티칼 테크놀로지 씨오., 엘티디 아트로핀 점안액 및 이의 제조 방법
US12396534B2 (en) 2021-10-08 2025-08-26 Johnson & Johnson Vision Care, Inc. Multi-material lens package
WO2023081891A2 (en) * 2021-11-05 2023-05-11 Calm Water Therapeutics Llc Methods for using bioadhesive and steric interactions of copolymers with at least two moieties to minimize adverse effects mediated by external influences on cell, tissue, organ system, and organism biology
WO2023172240A1 (en) * 2022-03-07 2023-09-14 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
WO2023171989A1 (ko) * 2022-03-11 2023-09-14 주식회사 메디치바이오 안질환 예방 또는 치료용 약학 조성물
EP4698187A2 (en) * 2022-05-03 2026-02-25 IVIEW Therapeutics, Inc. Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases
WO2024015959A1 (en) 2022-07-15 2024-01-18 Praful Doshi Methods of making and using contact lenses including medicaments and stabilizers of labile components such as drugs
US20240033260A1 (en) * 2022-07-26 2024-02-01 The Chinese University Of Hong Kong Low-concentration atropine for myopia prevention (lamp-2) study
US20260083720A1 (en) * 2022-10-26 2026-03-26 Vyluma Inc. Childhood Atropine For Myopia Progression
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
US20240316028A1 (en) * 2023-03-16 2024-09-26 Glaukos Corporation Ophthalmic cream formulations and their uses
TW202525288A (zh) * 2023-10-26 2025-07-01 英商庫博光學國際有限公司 液體組合物
WO2025212792A1 (en) * 2024-04-03 2025-10-09 Sydnexis, Inc. Methods and compositions for increasing pupil dilation
WO2026038024A1 (en) * 2024-08-13 2026-02-19 Coopervision International Limited Liquid composition

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382124B1 (en) 1958-07-18 1994-10-04 Rohm & Haas Process for preparing macroreticular resins, copolymers and products of said process
NL284933A (https=) 1961-10-31
DE1518819B1 (de) 1965-04-03 1969-12-04 Basf Ag Loesungsvermittler fuer pharmazeutische Zwecke
SE352811B (https=) 1971-06-04 1973-01-15 Pharmacia Ab
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4952586A (en) 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3644984A1 (de) 1986-07-01 1988-07-07 Eberhardt Schlueter Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4852582A (en) 1987-09-11 1989-08-01 Pell Donald M Method and kit for measuring the effectiveness of bronchodilators
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
FR2638428B1 (fr) 1988-10-28 1990-12-28 Transphyto Sa Conditionnement pour liquides a epurer
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5259998A (en) 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5492689A (en) 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
FR2702660B1 (fr) 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US5840770A (en) 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5490938A (en) 1993-12-20 1996-02-13 Biopolymerix, Inc. Liquid dispenser for sterile solutions
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
CZ285636B6 (cs) 1995-02-07 1999-10-13 Ústav Makromolekulární Chemie Av Čr Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby
AU7528696A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US5900360A (en) 1996-04-10 1999-05-04 Welch; William J. Correction of genetic defects using chemical chaperones
US20030157187A1 (en) 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
US6149670A (en) 1999-03-11 2000-11-21 Alsius Corporation Method and system for treating cardiac arrest using hypothermia
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
IN185228B (https=) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
CA2374003C (en) 1999-05-17 2008-02-12 Aesgen, Inc. Improved cellular uptake of bioactive agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CN1323595A (zh) 2000-05-11 2001-11-28 朱卫国 用于青光眼的药物组合物
US20050251254A1 (en) 2000-06-02 2005-11-10 Brady Daniel G Method of implanting accommodating intraocular lenses
WO2002015878A1 (fr) 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1397132A4 (en) 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
CN1206988C (zh) 2002-05-10 2005-06-22 刘继东 硫酸阿托品眼用凝胶
MXPA06001776A (es) 2003-08-15 2007-09-07 Qlt Usa Inc Sistema de suministro de farmaco transmucosal biocorrosivo, adhesivo.
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
NZ579516A (en) 2004-01-27 2011-01-28 Osteotech Inc Stabilized bone graft
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7659260B2 (en) 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
AU2006210416A1 (en) 2005-02-04 2006-08-10 Auburn University Contact drug delivery system
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
US20100022495A1 (en) 2005-11-01 2010-01-28 President And Fellows Of Harvard College Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN101049287A (zh) * 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US7691099B2 (en) * 2006-07-12 2010-04-06 Ntk Enterprises, Inc. Deuterated ocular solutions for LTK and other surgical eye procedures
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
CN101327216A (zh) 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
CN101820917B (zh) * 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
US7815605B2 (en) 2007-11-28 2010-10-19 Souter Steve R Emergency medication pump injection system
CN101468214A (zh) * 2007-12-27 2009-07-01 上海华捷视医疗设备有限公司 一种眼科手术用重水及其制备方法
DK2110132T3 (da) 2008-04-20 2014-04-28 D2 Bioscience Group Ltd Anvendelse af deuteriumoxid som elastasehæmmer
EP2370054B1 (en) 2008-12-11 2015-10-07 Massachusetts Institute of Technology Contact lens drug delivery device
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
WO2010083129A2 (en) * 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
TW201043211A (en) 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
US20120203161A1 (en) * 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
FR2950036B1 (fr) 2009-09-11 2011-12-16 Rexam Pharma La Verpilliere Dispositif de distribution de liquide
FR2952040B1 (fr) 2009-10-29 2011-12-30 Rexam Pharma La Verpilliere Dispositif de distribution de liquide sous forme de gouttes
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
US8945101B2 (en) * 2010-04-30 2015-02-03 Seros Medical, Llc Method and apparatus for treatment of ocular tissue using combine modalities
TWI424663B (zh) 2010-07-01 2014-01-21 Joy Ride Tech Co Ltd A motor with heat pipe
AU2011278934B2 (en) 2010-07-15 2015-02-26 Eyenovia, Inc. Drop generating device
EP2485691B1 (en) 2010-07-15 2020-03-18 Eyenovia, Inc. Ophthalmic drug delivery
JP5823766B2 (ja) * 2010-07-30 2015-11-25 大塚製薬株式会社 医薬組成物
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
BR112013021048A2 (pt) * 2011-02-18 2016-10-18 M S Appasmy Associates composição oftálmica para permitir dilatação de pupilas
JP2014506936A (ja) 2011-03-03 2014-03-20 アラーガン インコーポレイテッド シリコーンベースの眼科製剤
WO2012136969A2 (en) 2011-04-05 2012-10-11 Anant Sharma Ophthalmic treatments
JP6072009B2 (ja) 2011-05-12 2017-02-01 フォーサイト・バイオセラピューティクス・インコーポレーテッド ステロイド又は非ステロイド性抗炎症薬のある安定なポビドンヨード組成物
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
TW201302244A (zh) 2011-07-08 2013-01-16 Univ Nat Chiao Tung 載藥型隱形眼鏡及其製備方法
WO2013079580A1 (en) 2011-11-29 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
US20170304152A1 (en) 2012-02-01 2017-10-26 Certa Dose, Inc. Apparatuses, methods, and systems for delivering medication using medication kits
JP5345746B1 (ja) * 2012-02-27 2013-11-20 ロート製薬株式会社 眼科用組成物
US9814729B2 (en) 2012-03-14 2017-11-14 The Regents Of The University Of California Nerve agent antidotes
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
CA2872958A1 (en) 2012-05-11 2013-11-14 Cipla Limited Pharmaceutical composition
SG11201407428YA (en) 2012-05-14 2014-12-30 Eyenovia Inc Laminar flow droplet generator device and methods of use
AU2013262787A1 (en) 2012-05-15 2015-01-22 Eyenovia, Inc. Ejector devices, methods, drivers, and circuits therefor
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
HK1211867A1 (en) 2012-08-24 2016-06-03 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
WO2014140105A1 (en) 2013-03-13 2014-09-18 D2 Bioscience Group Ltd. Materials and compositions for dental cements and filler materials
US20160018671A1 (en) 2013-03-29 2016-01-21 Onefocus Technology, Llc Drug delivery from contact lenses with a fluidic module
JP6208332B2 (ja) 2013-05-06 2017-10-04 カオシュン・チャン・グン・メモリアル・ホスピタル 医薬組成物及びその用途
HUE033587T2 (hu) 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
DE102013218802B4 (de) 2013-09-19 2018-06-28 Aero Pump Gmbh Abgabevorrichtung für Fluide aus einem Fluidbehälter
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
CN106572941B (zh) 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂
DE102015104646B3 (de) 2015-03-26 2016-06-30 Aero Pump Gmbh Abgabevorrichtung für ein Fluid
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
CN117205209A (zh) 2016-05-25 2023-12-12 新加坡保健服务集团 含有阿托品的水性组合物
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
GEP20217239B (en) 2016-09-19 2021-03-25 Mexichem Fluor Sa De Cv Pharmaceutical composition
PH12019501945B1 (en) 2017-02-21 2024-02-21 Singapore Health Serv Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
CA3070556A1 (en) 2017-07-20 2019-01-24 Alan Laboratories, Inc. Compositions and methods for treatment of myopia
US20200345542A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
IL293859A (en) 2019-12-16 2022-08-01 Sydnexis Inc Ophthalmic preparations that include d2o

Also Published As

Publication number Publication date
NO2025049I1 (no) 2025-11-26
US20240165098A1 (en) 2024-05-23
SG10201913976SA (en) 2020-03-30
DK3160471T3 (da) 2022-08-15
SI3160471T1 (sl) 2022-10-28
HUS2500044I1 (hu) 2025-12-28
EP3160471A4 (en) 2018-04-04
LT3160471T (lt) 2022-11-10
CA2953363A1 (en) 2015-12-30
IL249643B (en) 2021-10-31
SMT202200447T1 (it) 2023-01-13
US20190091213A1 (en) 2019-03-28
BR112016030368A2 (pt) 2018-07-17
US11596625B2 (en) 2023-03-07
KR20170018962A (ko) 2017-02-20
JP2026064997A (ja) 2026-04-14
SG11201610682UA (en) 2017-01-27
CY1125505T1 (el) 2026-02-25
US11896588B2 (en) 2024-02-13
US9421199B2 (en) 2016-08-23
KR102506109B1 (ko) 2023-03-03
TW202237110A (zh) 2022-10-01
EP3689350A1 (en) 2020-08-05
JP6678362B2 (ja) 2020-04-08
HRP20220972T1 (hr) 2022-11-25
FR25C1045I1 (fr) 2026-01-02
WO2015200361A1 (en) 2015-12-30
US11883390B2 (en) 2024-01-30
KR20240144477A (ko) 2024-10-02
JP2022062045A (ja) 2022-04-19
US20180042911A1 (en) 2018-02-15
US20230091109A1 (en) 2023-03-23
JP7505888B2 (ja) 2024-06-25
US11382909B2 (en) 2022-07-12
CN106572998B (zh) 2019-11-08
US9770447B2 (en) 2017-09-26
US20230093205A1 (en) 2023-03-23
US20200085813A1 (en) 2020-03-19
PL3160471T3 (pl) 2022-09-26
CA2953363C (en) 2024-02-27
US20180193326A1 (en) 2018-07-12
EP4115884A1 (en) 2023-01-11
JP2017522292A (ja) 2017-08-10
CN106572998A (zh) 2017-04-19
TWI855319B (zh) 2024-09-11
US11890277B2 (en) 2024-02-06
CN110638749A (zh) 2020-01-03
HUE059521T2 (hu) 2022-11-28
EP3160471B1 (en) 2022-06-01
ES2924243T3 (es) 2022-10-05
TWI867694B (zh) 2024-12-21
KR20200001612A (ko) 2020-01-06
US20190298707A1 (en) 2019-10-03
JP2020097599A (ja) 2020-06-25
KR102710491B1 (ko) 2024-09-25
RS63486B1 (sr) 2022-09-30
US20230092957A1 (en) 2023-03-23
TW201613588A (en) 2016-04-16
BR112016030368B1 (pt) 2022-11-01
US10864208B2 (en) 2020-12-15
US20210059998A1 (en) 2021-03-04
US10076515B2 (en) 2018-09-18
CN115192520A (zh) 2022-10-18
IL249643A0 (en) 2017-02-28
SG10201707617VA (en) 2017-10-30
JP2024050526A (ja) 2024-04-10
US20160339007A1 (en) 2016-11-24
JP2025131595A (ja) 2025-09-09
PT3160471T (pt) 2022-08-09
TWI763620B (zh) 2022-05-11
US10201534B2 (en) 2019-02-12
US10842787B2 (en) 2020-11-24
US20150366854A1 (en) 2015-12-24
TW202412797A (zh) 2024-04-01
TW202510877A (zh) 2025-03-16
EP3160471A1 (en) 2017-05-03
US20210213008A9 (en) 2021-07-15
KR20210116688A (ko) 2021-09-27

Similar Documents

Publication Publication Date Title
FIC20250034I1 (fi) O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL254734B1 (en) Modified t cells and methods of making and using the same
IL248979B (en) Syntac polypeptides and uses thereof
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
SI3536685T1 (sl) Biciklične kondenzirane heteroarilne ali arilne sestavine in njihova uporaba kot zaviralci IRAK-4
FR3018941B1 (fr) Pilotage de vehicules en convoi
DK3237418T3 (da) Triazolopyrimidinforbindelser og anvendelser deraf
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
EP4135127C0 (en) MICRO-ASSEMBLY STRATEGIES AND DEVICES FOR COMPOUNDS
SI3258951T1 (sl) Anti-pvrig protitelesa in metode uporabe
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
HRP20181742T1 (hr) Hidroksialkil-supstituirani derivati feniltriazola i njihova uporaba
DK3152607T3 (da) En antiresonant hulkernefiber
FI20145087A7 (fi) Parannettu gyroskooppirakenne ja gyroskooppi
ME03558B (me) Molekuli anti-lag-3 antiтela i njihove upotrebe
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
SI3218005T1 (sl) Z glikanom delujoče spojine, in postopki uporabe
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
ZA201605760B (en) Immobilized proteins and use thereof
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
HUE044153T2 (hu) Apilimod melanóma kezelésében történõ alkalmazásra
SI3337506T1 (sl) Kombinacije in njihove uporabe